PFG Investments LLC Has $7.15 Million Stock Holdings in Pfizer Inc. $PFE

PFG Investments LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 12.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 280,558 shares of the biopharmaceutical company’s stock after purchasing an additional 30,084 shares during the period. PFG Investments LLC’s holdings in Pfizer were worth $7,149,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Symphony Financial Ltd. Co. raised its stake in shares of Pfizer by 14.0% during the 3rd quarter. Symphony Financial Ltd. Co. now owns 73,703 shares of the biopharmaceutical company’s stock worth $1,900,000 after purchasing an additional 9,026 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in Pfizer in the third quarter valued at approximately $3,019,000. Mn Services Vermogensbeheer B.V. grew its position in Pfizer by 1.8% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 2,159,000 shares of the biopharmaceutical company’s stock worth $55,011,000 after acquiring an additional 38,800 shares in the last quarter. Coordinated Financial Services Inc. increased its stake in shares of Pfizer by 29.0% during the 3rd quarter. Coordinated Financial Services Inc. now owns 11,800 shares of the biopharmaceutical company’s stock worth $301,000 after purchasing an additional 2,650 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators raised its holdings in shares of Pfizer by 12.4% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 47,113 shares of the biopharmaceutical company’s stock valued at $1,200,000 after purchasing an additional 5,203 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: NICE recommended Pfizer’s PARP inhibitor Talzenna for adults with prostate cancer — a UK endorsement that supports incremental oncology revenue and validates Pfizer’s targeted‑therapy strategy. NICE backs Pfizer’s Talzenna for adults with prostate cancer
• Positive Sentiment: Pfizer launched a large Phase 3 lung‑cancer trial positioning its regimen against Merck’s Keytruda — a successful outcome would target a high‑value oncology market and materially boost long‑term growth expectations. Pfizer Takes Aim at Keytruda in New Phase 3 Lung Cancer Study: What Investors Should Know
• Positive Sentiment: Pfizer moved a COPD candidate into a Phase 2/3 trial, strengthening its post‑COVID respiratory pipeline and the company’s addressable market in chronic lung disease. Pfizer Advances New COPD Candidate Into Phase 2/3, Adding Depth to Its Post-COVID Pipeline
• Positive Sentiment: Novavax and Pfizer reached a licensing agreement on the Matrix‑M adjuvant — this could reshape Pfizer’s vaccine platform strategy by expanding adjuvant options and serviceable vaccine markets. Novavax inks license agreement with Pfizer
• Positive Sentiment: Early‑stage pipeline progress: PF‑07248144 advanced with a drug–interaction study and PF‑08065010 entered Phase 1 — steady, low‑visibility pipeline work that reduces binary risk over time. Pfizer Advances PF-07248144 With New Drug–Interaction Study, Signaling Quiet Pipeline Progress
• Neutral Sentiment: Large options flow: traders bought ~446,836 call options (≈+114% vs. typical volume) — indicates short‑term bullish/speculative positioning but not a direct fundamental signal. (Market data)
• Neutral Sentiment: CEO Albert Bourla publicly criticized RFK Jr.’s vaccine views and warned the U.S. risks falling behind China in health research — a strong management stance on science and policy that can influence regulatory/public perception but is not an immediate earnings driver. Pfizer CEO Calls RFK’s Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research
• Negative Sentiment: Investor concerns persist on pricing and post‑COVID revenue sustainability — recent pieces question whether Pfizer’s current valuation reflects secular headwinds and pricing pressure, which helps explain selling pressure despite pipeline news. Is Pfizer (PFE) Pricing Make Sense After Post Covid Slowdown Concerns
• Negative Sentiment: Opinion pieces highlight a debate whether Pfizer is an attractive dividend/value play or a value trap — ongoing skepticism around growth prospects can keep the stock depressed. Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?

Pfizer Stock Down 1.7%

Shares of PFE stock opened at $25.65 on Friday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The firm has a market cap of $145.82 billion, a PE ratio of 14.91 and a beta of 0.47. The stock has a 50 day moving average of $25.40 and a 200-day moving average of $25.01.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The business had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent research reports. TD Cowen reiterated a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Scotiabank assumed coverage on Pfizer in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price target for the company. Citigroup initiated coverage on Pfizer in a report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price objective on the stock. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Finally, Morgan Stanley dropped their price target on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Friday, December 12th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $27.88.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.